Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-01-11
1999-02-02
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, 435455, 435456, 435479, 435 691, 435325, 935 11, 935 32, 800 18, C12N 1563, C12N 500, A01N 4304, A61K 3170
Patent
active
058665510
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
"This 371 application claims the benefit of PCT/FR94/00422, filed Nov. 10, 1994, which claims the benefit of French application FR93/05125, filed Apr. 30, 1993."
The present invention relates to new recombinant viruses, to their preparation and to their use in gene therapy, for the transfer and expression in vivo of desired genes. More specifically, it relates to new recombinant viruses comprising an inserted gene whose expression in vivo makes it possible to regulate the plasma levels of apolipoproteins. The present invention also relates to pharmaceutical compositions comprising the said recombinant viruses. More particularly, the present invention relates to defective recombinant viruses and to their use for the prevention or treatment of pathologies linked to dyslipoproteinemias which are known for their serious consequences at the cardiovascular and neurological level.
2. Description of Related Art
Dyslipoproteinemias are disorders of the metabolism of the lipoproteins responsible for the transport, in the blood and peripheral fluids, of lipids such as cholesterol and triglycerides. They result in major pathologies, linked respectively to hypercholesterolemia or hypertriglyceridemia, such as especially atherosclerosis. Atherosclerosis is a polygenic complex disease which is defined from the histological point of view by deposits (lipid or fibrolipid plaques) of lipids and of other blood derivatives in the wall of the large arteries (aorta, coronary arteries, carotid). These plaques, which are calcified to a greater or lesser extent according to the progression of their process, can be associated with lesions and are linked to the accumulation, in the arteries, of fatty deposits consisting essentially of cholesterol esters. These plaques are accompanied by a thickening of the arterial wall, with hypertrophy of the smooth muscle, the appearance of spumous cells and the accumulation of fibrous tissue. The atheromatous plaque is very clearly in relief on the wall, which confers on it a stenosing character responsible for vascular occlusions by atheroma, thrombosis or embolism which occur in the patients most affected. Hypercholosterolemias can therefore result in very serious cardiovascular pathologies such as infarct, sudden death, cardiac decompensation, cerebral vascular accidents and the like.
It is therefore particularly important to be able to have available treatments which make it possible to reduce, in certain pathological situations, the plasma cholesterol levels or even to stimulate the efflux of cholesterol (reverse transport of the cholesterol) in the peripheral tissues in order to discharge the cells having accumulated cholesterol within the context of the formation of an atheroma plaque. The cholesterol is carried in the blood by various lipoproteins including the low-density lipoproteins (LDL) and the high-density lipoproteins (HDL). The LDLs are synthesized in the liver and make it possible to supply the peripheral tissues with cholesterol. In contrast, the HDLs capture cholesterol in the peripheral tissues and transport it to the liver where it is stored and/or degraded.
At present, dyslipemias and in particular hypercholesterolemias are treated essentially by means of compounds which act either on the biosynthesis of cholesterol (inhibitors of hydroxymethylglutaryl-coenzymeA reductase, statins), or on the capture and elimination of bile cholesterol (sequestrants or resins), or alternatively on lipolysis by a mode of action which remains to be elucidated from the molecular point of view (fibrates). Consequently, all the major categories of drugs which have been used in this indication (sequestrants, fibrates or statins), are designed only for the preventive aspect of the formation of the atheroma plaque and not in fact for the treatment of the atheroma. The current treatment for atheroma, following a coronary accident, are only palliative since they do not act on cholesterol homeostasis and they are surgical acts (coronary by-pass, a
REFERENCES:
Embase Database Abstracts 9200254, Frolkis et al. 1991.
WPI Database Abstracts 89-119, 1989.
Coghland, Focus, vol. 145, pp. 14-15, Nov. 25, 1995.
Brown, "News Media Researchers `Oversold` Gene Therapy . . . Says", The Washington Post, Dec. 8, 1995.
Mulligan, Science, vol. 260, pp. 926-930, May 14, 1993.
Chan, Current Opinion in Lipidology, vol. 6, pp. 335-340, Oct. 1995.
Bramson et al., Current Opinion in Biotechnology, vol. 6, pp. 590-595, Oct. 1995.
Kashyap et al., Journal of Clinical Investigation, vol. 96, pp.1612-1620, Sep. 1995.
Rojanasakul, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.
Marshall, Science, vol. 269, pp. 1050-1055, Aug. 25, 1995.
Orkin & Motulsky, The Report and Recommendations of the Panel . . . Gene Therapy, Dec. 7, 1995.
Karathanasis et al., Proc. Natl. Acad. Sci., vol. 80, pp. 6147-6151, Oct. 1983.
Rosenfield et al., Cell, vol. 68, pp. 143-155, Dec. 10, 1992.
Benoit Patrick
Denefle Patrice
Perricaudet Michel
Seguret Sandrine
Vigne Emmanuelle
Chambers Jasemine C.
Rhone-Poulenc Rorer S.A.
Schmuck Jill D.
LandOfFree
Recombinant adero viruses comprising an inserted gene encoding a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant adero viruses comprising an inserted gene encoding a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adero viruses comprising an inserted gene encoding a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117529